Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167180 · ClinicalTrials.gov registry record · Phase 2
Post Transplant Donor Lymphocyte Infusion
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00167180 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 57 participants.
The verdict
NCT00167180, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
Interventions
- PROCEDURE Donor Lymphocyte Infusion
- DRUG Induction Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-01 |
| Est. Completion | 2018-12-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167180
The ClinicalTrials.gov registry entry for NCT00167180 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donor Lymphocyte Infusion is the first listed.
NCT00167180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167180 about?
NCT00167180 is a clinical study titled "Post Transplant Donor Lymphocyte Infusion". The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
What is the current status of trial NCT00167180?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2004-01. Estimated completion is 2018-12-24.
What interventions are being tested in trial NCT00167180?
The interventions under investigation include: Donor Lymphocyte Infusion (PROCEDURE), Induction Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00167180?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.